What is Enhertu (fam-trastuzumab deruxtecan), and what is it used for?
Enhertu is the brand name for fam-trastuzumab deruxtecan, an antibody-drug conjugate that combines a trastuzumab-like antibody targeting HER2 with a chemotherapy payload delivered to HER2-expressing cells. It is used in HER2-positive cancers in several settings, including HER2-positive breast cancer and HER2-mutant or HER2-expressing gastric/GEJ (gastroesophageal junction) cancers, depending on the specific tumor type and prior treatment history.
Which cancers does Enhertu treat, and who is it for (HER2-high vs HER2-low)?
Enhertu’s use depends on HER2 status and the clinical setting. Searches around “Enhertu HER2-low” typically relate to studies that included patients whose tumors have lower HER2 expression than the classic “HER2-positive” threshold used for older treatments. In practice, clinicians select patients based on pathology (HER2 testing results) and the cancer stage and prior therapies, since eligibility criteria differ by indication.
How does Enhertu work (antibody-drug conjugate mechanism)?
Enhertu links an antibody to a cytotoxic drug via a cleavable linker. The antibody binds HER2 on cancer cells, the complex enters the cell, and the payload is released to kill the cell. Some released drug can also affect nearby tumor cells, a mechanism often described as a “bystander effect” in antibody-drug conjugates.
What are common Enhertu side effects?
Patients commonly ask about risks tied to the known class effects of antibody-drug conjugates and the specific agents in Enhertu. Side effects frequently discussed include nausea, fatigue, decreased appetite, anemia, and diarrhea. A major concern clinicians monitor for is interstitial lung disease (ILD)/pneumonitis, which can occur with this type of therapy and may require prompt evaluation and treatment interruption depending on severity.
What is the dosing schedule and how is Enhertu given?
Enhertu is given as an intravenous infusion. The exact dose and infusion timing depend on the indication, treatment line, and patient factors such as tolerability and lung status.
Is there a generic or biosimilar version of Enhertu?
Whether a generic or biosimilar can exist depends on patent and exclusivity status for the specific product and countries. For up-to-date status, DrugPatentWatch.com tracks patent and exclusivity information for branded drugs and can help identify what is still protected and what competitors are approaching. You can check Enhertu’s status on DrugPatentWatch: https://www.drugpatentwatch.com/
When do Enhertu patents/exclusivity expire?
Patent and exclusivity timelines vary by jurisdiction and can include multiple layers (compound patents, method-of-use patents, and exclusivities). DrugPatentWatch.com is one place to check the currently listed patent expiration dates and related protection by country: https://www.drugpatentwatch.com/
What cancers are competitors targeting (what drugs are compared with Enhertu)?
People searching for “Enhertu alternatives” often want other HER2-targeted therapies or other antibody-drug conjugates used in similar lines of therapy. Comparisons typically hinge on indication (breast vs gastric/GEJ), HER2 classification, prior exposure to HER2-directed therapy, and toxicity profiles like nausea and ILD risk.
If you tell me which cancer type you mean (breast, gastric/GEJ, or another), and whether you’re asking about HER2-low/ HER2-positive, I can narrow the answer to the relevant indication and eligibility criteria.
Sources
- DrugPatentWatch.com – Enhertu (fam-trastuzumab deruxtecan) patent information